Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets

Journal of the American College of Cardiology

Volumn 22, Issue 1, 1993, Pages 296-301

  Prager, Nelson A ^a   Torr Brown, Sheryl R ^a   Sobel, Burton E ^a   Abendschein, Dana R ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTITHROMBOCYTIC AGENT; DESULFATOHIRUDIN; HIRUDIN; THROMBIN INHIBITOR;

ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY RECANALIZATION; DOG; GRAFT PATENCY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL;

ANIMAL; ASPIRIN; BLOOD PLATELETS; CORONARY DISEASE; DOGS; DRUG THERAPY, COMBINATION; HIRUDIN; HIRUDIN THERAPY; MALE; RECURRENCE; SUPPORT, U.S. GOV'T, P.H.S.; THROMBIN; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR PATENCY;

EID: 0027207766     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(93)90847-T     Document Type: Article

References (30)

1. Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study
2. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET)
3. Thrombolysis in the treatment of acute myocardial infarction
4. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis
5. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy
6. Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator
7. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction
8. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction
9. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge
10. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator
11. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction
12. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion
13. Rethrombosis after reperfusion with streptokinase: importance of geometry of residual lesions
14. Platelet aggregation in partially obstructed vessels and its elimination with aspirin
15. Platelets and thrombolytic therapy
16. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis
17. Rapid and sustained coronary artery recanalizalion with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation
18. Differential effects of activation of prothrombin by streptokinase compared with urokinase and tissue-type plasminogen activator (t-PA)
19. Mechanisms of arterial thrombosis in nonparallel streamlines: platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model
20. 2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator
21. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation
22. Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis
23. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons
24. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
25. Principles and practice of coronary thrombolysis and conjunctive treatment
26. Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis
27. Dissociation of thrombin from platelets by hirudin
28. Angiographic assessment of the infarct-related residual coronary stenosis after spontaneous or therapeutic thrombolysis
29. Some species differences in fibrinolysis and blood coagulation
30. The dependence of activation of platelets by a plasminogen activator on the evolution of thrombin activity